1. Home
  2. ADTX vs ONCO Comparison

ADTX vs ONCO Comparison

Compare ADTX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aditxt Inc.

ADTX

Aditxt Inc.

N/A

Current Price

$0.28

Market Cap

641.6K

Sector

Health Care

ML Signal

N/A

Logo Onconetix Inc.

ONCO

Onconetix Inc.

N/A

Current Price

$0.67

Market Cap

755.3K

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADTX
ONCO
Founded
2017
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
641.6K
755.3K
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
ADTX
ONCO
Price
$0.28
$0.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
914.0K
13.1M
Earning Date
05-14-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
62.32
22.80
EPS
N/A
N/A
Revenue
$3,195.00
$815,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.06
52 Week High
$7.13
$7.65

Technical Indicators

Market Signals
Indicator
ADTX
ONCO
Relative Strength Index (RSI) 33.49 41.90
Support Level $0.05 $0.51
Resistance Level $1.11 $0.95
Average True Range (ATR) 0.05 0.26
MACD -0.01 -0.06
Stochastic Oscillator 2.16 0.66

Price Performance

Historical Comparison
ADTX
ONCO

About ADTX Aditxt Inc.

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: